GB1553595A - Pyrrolidones and process for their manufacture - Google Patents
Pyrrolidones and process for their manufactureInfo
- Publication number
- GB1553595A GB1553595A GB26564/76A GB2656476A GB1553595A GB 1553595 A GB1553595 A GB 1553595A GB 26564/76 A GB26564/76 A GB 26564/76A GB 2656476 A GB2656476 A GB 2656476A GB 1553595 A GB1553595 A GB 1553595A
- Authority
- GB
- United Kingdom
- Prior art keywords
- formula
- properties
- pyrrolidones
- image
- hand
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 150000004040 pyrrolidinones Chemical class 0.000 title abstract 2
- 238000004519 manufacturing process Methods 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 230000003276 anti-hypertensive effect Effects 0.000 abstract 1
- 239000008280 blood Substances 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 abstract 1
- 230000003182 bronchodilatating effect Effects 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 210000004051 gastric juice Anatomy 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 230000028327 secretion Effects 0.000 abstract 1
- 230000003033 spasmogenic effect Effects 0.000 abstract 1
- 230000002048 spasmolytic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/24—Oxygen or sulfur atoms
- C07D207/26—2-Pyrrolidones
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pyrrole Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19752528664 DE2528664A1 (de) | 1975-06-27 | 1975-06-27 | Pyrrolidone und verfahren zu ihrer herstellung |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| GB1553595A true GB1553595A (en) | 1979-09-26 |
Family
ID=5950059
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GB26564/76A Expired GB1553595A (en) | 1975-06-27 | 1976-06-25 | Pyrrolidones and process for their manufacture |
Country Status (14)
Cited By (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003009872A1 (en) | 2001-07-23 | 2003-02-06 | Ono Pharmaceutical Co., Ltd. | Remedies for diseases with bone mass loss having ep4 agonist as the active ingredient |
| WO2003077910A1 (en) * | 2002-03-18 | 2003-09-25 | Pfizer Products Inc. | Methods of treatment with selective ep4 receptor agonists |
| US6642266B2 (en) | 1999-12-22 | 2003-11-04 | Pfizer Inc. | EP4 receptor selective agonists in the treatment of osteoporosis |
| US6747054B2 (en) | 2000-11-27 | 2004-06-08 | Pfizer Inc. | EP4 receptor selective agonists in the treatment of osteoporosis |
| US6849657B2 (en) | 2001-07-16 | 2005-02-01 | Syntex (U.S.A.) Llc | 2-pyrrolidone derivatives as prostanoid agonists |
| US6900336B2 (en) | 2001-07-16 | 2005-05-31 | Syntex (U.S.A.) Llc | 8-aza-11-deoxy prostaglandin analogues |
| US7179820B2 (en) | 2003-06-06 | 2007-02-20 | Allergan, Inc. | Piperidinyl prostaglandin E analogs |
| US7271183B2 (en) | 2003-01-10 | 2007-09-18 | Roche Palo Alto Llc | 2-Piperidone derivatives as prostaglandin agonists |
| US9180116B2 (en) | 2012-07-19 | 2015-11-10 | Cayman Chemical Company, Inc. | Difluorolactam compounds as EP4 receptor-selective agonists for use in the treatment of EP4-mediated diseases and conditions |
| US9676712B2 (en) | 2013-03-15 | 2017-06-13 | Cayman Chemical Company, Inc. | Lactam compounds as EP4 receptor-selective agonists for use in the treatment of EP4-mediated diseases and conditions |
| US9688627B2 (en) | 2013-03-15 | 2017-06-27 | Cayman Chemical Company, Inc. | Lactam compounds as EP4 receptor-selective agonists for use in the treatment of EP4-mediated diseases and conditions |
| US9914725B2 (en) | 2013-03-15 | 2018-03-13 | Cayman Chemical Company, Inc. | Methods of synthesizing a difluorolactam analog |
| US10729810B2 (en) | 2013-07-19 | 2020-08-04 | Cayman Chemical Company, Inc | Methods, systems, and compositions for promoting bone growth |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE423813B (sv) * | 1976-08-06 | 1982-06-07 | Pfizer | Forfarande for framstellning av 1,5-disubstituerade pyrrolidoner med terapeutiska egenskaper |
| US4772601A (en) * | 1988-01-25 | 1988-09-20 | Hoechst-Roussel Pharmaceuticals, Inc. | 5-Substituted 1-(4-(1-pyrrolidinyl)-2-butynyl)-2-pyrrolidinones, pharmaceutical compositions and use |
| WO2002024647A1 (fr) * | 2000-09-21 | 2002-03-28 | Ono Pharmaceutical Co., Ltd. | Agonistes du recepteur de l'ep4 comprenant comme principe actif des derives de la 8-azaprostaglandine |
| US6573294B1 (en) | 2002-05-14 | 2003-06-03 | Allergan, Inc. | 8-azaprostaglandin analogs as agents for lowering intraocular pressure |
-
1975
- 1975-06-27 DE DE19752528664 patent/DE2528664A1/de not_active Withdrawn
-
1976
- 1976-06-22 ES ES449095A patent/ES449095A1/es not_active Expired
- 1976-06-22 NL NL7606773A patent/NL7606773A/xx not_active Application Discontinuation
- 1976-06-24 CH CH809976A patent/CH623809A5/de not_active IP Right Cessation
- 1976-06-24 SE SE7607331A patent/SE7607331L/xx unknown
- 1976-06-24 LU LU75235A patent/LU75235A1/xx unknown
- 1976-06-25 DK DK287476A patent/DK287476A/da unknown
- 1976-06-25 AT AT0467976A patent/AT365575B/de active
- 1976-06-25 ZA ZA763802A patent/ZA763802B/xx unknown
- 1976-06-25 GB GB26564/76A patent/GB1553595A/en not_active Expired
- 1976-06-25 IL IL49916A patent/IL49916A0/xx unknown
- 1976-06-26 JP JP51075954A patent/JPS525764A/ja active Pending
- 1976-06-28 BE BE168390A patent/BE843505A/xx not_active IP Right Cessation
- 1976-06-28 FR FR7619563A patent/FR2316943A1/fr active Granted
Cited By (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6642266B2 (en) | 1999-12-22 | 2003-11-04 | Pfizer Inc. | EP4 receptor selective agonists in the treatment of osteoporosis |
| US6747054B2 (en) | 2000-11-27 | 2004-06-08 | Pfizer Inc. | EP4 receptor selective agonists in the treatment of osteoporosis |
| US7192979B2 (en) | 2000-11-27 | 2007-03-20 | Pfizer Inc. | EP4 receptor selective agonist in the treatment of osteoporosis |
| US6849657B2 (en) | 2001-07-16 | 2005-02-01 | Syntex (U.S.A.) Llc | 2-pyrrolidone derivatives as prostanoid agonists |
| US6900336B2 (en) | 2001-07-16 | 2005-05-31 | Syntex (U.S.A.) Llc | 8-aza-11-deoxy prostaglandin analogues |
| WO2003009872A1 (en) | 2001-07-23 | 2003-02-06 | Ono Pharmaceutical Co., Ltd. | Remedies for diseases with bone mass loss having ep4 agonist as the active ingredient |
| US7608637B2 (en) | 2001-07-23 | 2009-10-27 | Ono Pharmaceutical Co., Ltd. | Pharmaceutical composition for treatment of diseases associated with decrease in bone mass comprising EP4 agonist as the active ingredient |
| EP2255829A2 (en) | 2001-07-23 | 2010-12-01 | Ono Pharmaceutical Co., Ltd. | Pharmaceutical composition for treatment of diseases associated with decrease in bone mass comprising EP4 agonist as active ingredient |
| US8207223B2 (en) | 2001-07-23 | 2012-06-26 | Ono Pharmaceutical Co., Ltd. | Pharmaceutical composition for treatment of diseases associated with decrease in bone mass comprising EP4 agonist as active ingredient |
| WO2003077910A1 (en) * | 2002-03-18 | 2003-09-25 | Pfizer Products Inc. | Methods of treatment with selective ep4 receptor agonists |
| US7271183B2 (en) | 2003-01-10 | 2007-09-18 | Roche Palo Alto Llc | 2-Piperidone derivatives as prostaglandin agonists |
| US7179820B2 (en) | 2003-06-06 | 2007-02-20 | Allergan, Inc. | Piperidinyl prostaglandin E analogs |
| US9180116B2 (en) | 2012-07-19 | 2015-11-10 | Cayman Chemical Company, Inc. | Difluorolactam compounds as EP4 receptor-selective agonists for use in the treatment of EP4-mediated diseases and conditions |
| US9440919B2 (en) | 2012-07-19 | 2016-09-13 | Cayman Chemical Company, Inc. | Difluorolactam compositions for EP4-mediated osteo related diseases and conditions |
| US9487478B2 (en) | 2012-07-19 | 2016-11-08 | Cayman Chemical Company, Inc. | Difluorolactam compounds as EP4 receptor-selective agonists for use in the treatment of EP4-mediated diseases and conditions |
| US9701630B2 (en) | 2012-07-19 | 2017-07-11 | Cayman Chemical Company, Inc. | Difluorolactam compositions for EP4-mediated osteo related diseases and conditions |
| US10556862B2 (en) | 2012-07-19 | 2020-02-11 | Cayman Chemical Company, Inc. | Difluorolactam compounds as EP4 receptor-selective agonists for use in the treatment of EP4-mediated diseases and conditions |
| US11066361B2 (en) | 2012-07-19 | 2021-07-20 | Cayman Chemical Company, Inc. | Difluorolactam compounds as EP4 receptor-selective agonists for use in the treatment of EP4-mediated diseases and conditions |
| US11884624B2 (en) | 2012-07-19 | 2024-01-30 | Cayman Chemical Company, Inc. | Difluorolactam compounds as EP4 receptor-selective agonists for use in the treatment of EP4-mediated diseases and conditions |
| US9676712B2 (en) | 2013-03-15 | 2017-06-13 | Cayman Chemical Company, Inc. | Lactam compounds as EP4 receptor-selective agonists for use in the treatment of EP4-mediated diseases and conditions |
| US9688627B2 (en) | 2013-03-15 | 2017-06-27 | Cayman Chemical Company, Inc. | Lactam compounds as EP4 receptor-selective agonists for use in the treatment of EP4-mediated diseases and conditions |
| US9914725B2 (en) | 2013-03-15 | 2018-03-13 | Cayman Chemical Company, Inc. | Methods of synthesizing a difluorolactam analog |
| US11345690B2 (en) | 2013-03-15 | 2022-05-31 | Cayman Chemical Company, Inc. | Methods of synthesizing a difluorolactam analog |
| US10729810B2 (en) | 2013-07-19 | 2020-08-04 | Cayman Chemical Company, Inc | Methods, systems, and compositions for promoting bone growth |
Also Published As
| Publication number | Publication date |
|---|---|
| IL49916A0 (en) | 1976-08-31 |
| DK287476A (da) | 1976-12-28 |
| DE2528664A1 (de) | 1977-01-13 |
| CH623809A5 (en) | 1981-06-30 |
| NL7606773A (nl) | 1976-12-29 |
| JPS525764A (en) | 1977-01-17 |
| FR2316943B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 1978-11-03 |
| SE7607331L (sv) | 1976-12-28 |
| ZA763802B (en) | 1977-05-25 |
| ATA467976A (de) | 1981-06-15 |
| AT365575B (de) | 1982-01-25 |
| FR2316943A1 (fr) | 1977-02-04 |
| BE843505A (fr) | 1976-12-28 |
| ES449095A1 (es) | 1977-12-16 |
| LU75235A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 1977-03-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GB1553595A (en) | Pyrrolidones and process for their manufacture | |
| HUT42080A (en) | Process for producing labdane derivatives and pharmaceutical compositions containing them | |
| JPS5251327A (en) | 3-trihydroxygermylpropionic acid and its salts and process for prepari ng the same | |
| CA934758A (en) | Process for the preparation of unsymmetrical 1,4-dihydropyridine 3,5-dicarboxylates | |
| PH13353A (en) | Process for the preparation of s-triazolo(%,*')benzothiazole | |
| JPS5257130A (en) | Process for preparation of methylphenols | |
| JPS51143669A (en) | A process for preparing 1,2,4- oxadiazole derivatives | |
| HUT49125A (en) | Process for producing new 2-thiazolidinone derivatives and pharmaceutical compositions containing them | |
| GR3003638T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | ||
| JPS5227734A (en) | Process for preparation of 2,6-dichloro- 4-methylphenol | |
| JPS51113870A (en) | A process for secretin synthesis | |
| CH613203A5 (en) | Process for the preparation of 4,4-diphenylcyclohexylpiperidine | |
| DE3476398D1 (en) | An anthracycline compound, a process for the production thereof, a pharmaceutical composition containing the same and its use as a medicament | |
| JPS51149210A (en) | Process for preparation of tetrafluoroethylene oligomers | |
| IL82936A (en) | 4-benzyloxy-3-pyrrolin-2-one,process for the preparation thereof and the use thereof for the preparation of tetramic acid | |
| JPS5242867A (en) | Process for preparation of 17alpha -(3-hydroxypropyl)- 17beta-hydroxy-androsto- 4 -ene-3-one | |
| JPS51143678A (en) | A process for preparing carbostyril derivatives | |
| JPS5212107A (en) | Process for preparation of farnesol or its 10,11-isopropylidenedioxy d erivative | |
| JPS5233623A (en) | Process for preparation of fluorosufonylehters | |
| JPS51133296A (en) | Processes for preparing 7-acylamino- 3-hydroxymethyl-2-cephem-4-carbox ylic acid derivatives | |
| JPS5246023A (en) | Process for preparation of organosulfinic acid salts | |
| JPS51111853A (en) | A method for accelerating crosslinking reaction of a polymen containin g halogen | |
| JPS5253894A (en) | Process for preparing 4-hydroxy-1h-pyrazolo 3,4-d pyrmidine | |
| JPS5231031A (en) | Process for preparation of substituted phosphonic acid derivatives | |
| JPS51150590A (en) | A process for preparing water-resistant pullulan |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PS | Patent sealed [section 19, patents act 1949] | ||
| PCNP | Patent ceased through non-payment of renewal fee |